Zobrazeno 1 - 10
of 32
pro vyhledávání: '"M. A. Panasenko"'
Publikováno v:
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 15, Iss 3, Pp 307-312 (2022)
Cardiac involvement is one of the most important prognostic markers in multiple myeloma. However, prognostic value of novel biomarkers, such as soluble suppression of tumorigenicity 2 (sST2), P-selectin is unknown in multiple myeloma. The aim of t
Externí odkaz:
https://doaj.org/article/ede665008c38437c80af3f0a38a63b38
Autor:
B. B. Samura, M. O. Panasenko
Publikováno v:
Zaporožskij Medicinskij Žurnal, Vol 24, Iss 5, Pp 613-624 (2022)
Heart dysfunction that occurred after using of anticancer drugs and monoclonal antibodies may be a limit factor in treatment of chronic lymphoproliferative diseases (CLPD). Cancer therapy-related cardiovascular toxicity include hypotension, hypertens
Externí odkaz:
https://doaj.org/article/253ccb852bc34515b86f3c74a0d1d219
Publikováno v:
Patologìâ, Vol 19, Iss 2, Pp 110-115 (2022)
Aim. We aimed to evaluate the prognostic value of circulating sST2 for cumulative cardiovascular events in patients with multiple myeloma. Materials and methods. Ninety seven patients with complete or partial remission of multiple myeloma were enr
Externí odkaz:
https://doaj.org/article/7c6c0f4c5d324fb788363667e313b811
Publikováno v:
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 15, Iss 2, Pp 186-191 (2022)
Multiple myeloma (MM) survival has greatly improved in recent decades. MM is usually diagnosed in elderlies. Patients do not necessarily die from MM, so cardiovascular health may be a key factor threatening long-term survival. The aim of the resea
Externí odkaz:
https://doaj.org/article/9a46165917934a50961a829f268e8989
Publikováno v:
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 13, Iss 3, Pp 437-444 (2020)
Multiple myeloma is a plasma cell clonal malignancy that accounts for 10 % of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities o
Externí odkaz:
https://doaj.org/article/a5e42e4eea784a0d9561bdd08ecf1c6d
Autor:
B. B. Samura, M. O. Panasenko
Publikováno v:
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 13, Iss 2, Pp 265-270 (2020)
Purpose – to evaluate the relations of antitumor treatment and cardiohemodynamics in patients with multiple myeloma depending on renal function. Materials and methods. Fifty-one subjects with multiple myeloma were enrolled in the study. They wer
Externí odkaz:
https://doaj.org/article/8920fac2e47b49f1b5862b680c63ace9
Autor:
B. B. Samura, M. O. Panasenko
Publikováno v:
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 13, Iss 1, Pp 164-172 (2020)
Heart dysfunction that occurred after using cytostatic drugs and monoclonal antibodies may be a limit factor in the treatment of multiple myeloma. Side effects of chemotherapy include hypotension, hypertension, arrhythmias, conduction disturbances, p
Externí odkaz:
https://doaj.org/article/5caddc34d970454186dea4a8c775a56f
Autor:
B. B. Samura, M. O. Panasenko
Publikováno v:
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 12, Iss 3, Pp 346-351 (2019)
Purpose – to evaluate cardiohemodanamics in patients with multiple myeloma depending on renal function. Materials and methods. Thirty-five subjects with multiple myeloma were enrolled in the study. They were divided into groups depending on the glo
Externí odkaz:
https://doaj.org/article/ee70992e839544309fbf912fcb2b393a
Autor:
L. P. Kuznetsova, M. O. Panasenko
Publikováno v:
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 12, Iss 2, Pp 222-227 (2019)
Most clinicians consider performance status and comorbidities rather than chronological age in determining prognosis and treatment. Significant advancements in the treatment of myeloma have occurred including routine use of proteasome inhibitors and
Externí odkaz:
https://doaj.org/article/6534943b48744b8eb4f1154f307d2aa8
Evaluation of the capacity for direct regeneration of maize inbreds of the Lancaster selection group
Autor:
K. V. Derkach, O. E. Abraimova, T. M. Satarova, O. A. Molitva, V. S. Kalugina, M. G. Panasenko, S. S. Pechorna
Publikováno v:
Vìsnik Dnìpropetrovsʹkogo Unìversitetu: Serìâ Bìologìâ, Ekologìâ, Vol 21, Iss 2, Pp 59-63 (2013)
In connection with the necessity of bringing elite maize inbreds of the Lancaster germplasm group, which have potential for cultivation in Ukraine, into the system of genetic tranformation, the aim of this investigation is to identify the ability of
Externí odkaz:
https://doaj.org/article/a00b2176896c4c758e5e33819507d027